Neuren Pharmaceuticals (ASX:NEU) and its partner Acadia Pharmaceuticals have announced access to an updated formulation of trofinetide.
The companies announced that DAYBUE STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation, is now broadly available in the United States for the treatment of Rett syndrome in adults and paediatric patients aged two and older.
The new formulation was approved by the US Food and Drug Administration in December 2025 and launched in the US on a limited basis in the first quarter of 2026.
The new formulation can be mixed into everyday liquids such as juice or tea, allowing caregivers to tailor administration to a patient’s preferences. This seemingly simple adjustment addresses a long-standing challenge in paediatric and neurological care, where adherence often depends on how easily a treatment can be integrated into daily routines.
The companies said feedback from the initial limited launch suggests that this approach is resonating, with more than 80 per cent of caregivers reporting satisfaction, particularly noting the convenience and portability of individual packet dosing.
For clinicians, it expands the toolkit for managing Rett syndrome, a condition with historically limited treatment options. For families, it offers a degree of autonomy and adaptability that aligns with the disorder's unpredictable and varied nature.
For Neuren, the development underscores its broader strategy of targeting neurological disorders linked to genetic abnormalities or brain injury through therapies based on insulin-like growth factor pathways. While trofinetide represents the company’s first major commercial success, its pipeline continues to advance, with NNZ 2591 being explored across several rare neurodevelopmental conditions and in later-stage trials for Phelan McDermid syndrome. These programs point to a sustained effort to address unmet needs in areas where therapeutic options remain scarce.